This study sought to determine the synergistic effects of age and HIV infection on medical co-morbidity burden, along with its clinical correlates and impact on health-related quality of life (HRQoL) across the lifespan in HIV. Participants included 262 individuals across four groups stratified by age (≤40 and ≥50 years) and HIV serostatus. Medical co-morbidity burden was assessed using a modified version of the Charlson Co-morbidity Index (CCI). Multiple regression accounting for potentially confounding demographic, psychiatric, and medical factors revealed an interaction between age and HIV infection on the CCI, with the highest medical co-morbidity burden in the older HIV+cohort. Nearly half of the older HIV+group had at least one major medical co-morbidity, with the most prevalent being diabetes (17.8%), syndromic neurocognitive impairment (15.4%), and malignancy (12.2%). Affective distress and detectable plasma viral load were significantly associated with the CCI in the younger and older HIV-infected groups, respectively. Greater co-morbidity burden was uniquely associated with lower physical HRQoL across the lifespan. These findings highlight the prevalence and clinical impact of co-morbidities in older HIV-infected adults and underscore the importance of early detection and treatment efforts that might enhance HIV disease outcomes.
Get full access to this article
View all access options for this article.
References
1.
Center for Disease Control and Prevention. HIV Surveillance Report, 2010. Atlanta: U.S. Department of Health and Human Services, CDC, 2011.
2.
HughesAK. HIV knowledge and attitudes among providers in aging: Results from a national survey. AIDS Patient Care STDs, 2011; 25:539–545.
3.
Center for Disease Control and Prevention. HIV Surveillance Report, 2008. Atlanta: U.S. Department of Health and Human Services, CDC 2009.
4.
BlancoJR, CaroAM, Pérez-CachafeiroSet al.HIV infection and aging. AIDS Rev, 2010; 12:218–230.
5.
ValcourV, ShikumaC, ShiramizuBet al.Higher frequency of dementia in older HIV-1 individuals: The Hawaii Aging with HIV-1 Cohort. Neurology, 2004; 63:822–827.
6.
PhillipsAN, LeeCA, ElfordJet al.More rapid progression to AIDS in older HIV-infected people: The role of CD4+ T-cell counts. J Acquir Immune Defic Syndr, 1991; 4:970–975.
7.
EggerM, CheneG, PhillipsANet al.Prognosis of HIV-1 infected patient starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet, 2002; 360:119–129.
8.
BamfordLM, EhrenkranzPD, EberhartMGet al.Factors associated with delayed entry into primary HIV medical care after HIV diagnosis. AIDS, 2010; 24:928–930.
9.
GardnerID. The effect of aging on susceptibility to infection. Rev Infect Dis, 1980; 2:801–810.
10.
MorganEE, IudicelloJE, WeberEet al.Synergistic effects of HIV infection and older age on daily functioning. J Acquir Immune Defic Syndr, 2012; 61:341–348.
11.
HighKP, Brennan-IngM, CliffordDBet al.HIV and aging: State of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr, 2012; 60:S1–S18.
12.
HernandezMD, ShermanKE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS, 2011; 6:478–482.
13.
McCutchanJA, Marquie-BeckJA, FitzsimmonsCAet al.Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorders. Neurology, 2012; 14:485–492.
14.
HinkinCH, CastellonSA, LevineAJet al.Neurocognition in individuals co-infected with HIV and hepatitis C. J Addictive Dis, 2008; 27:11–17.
15.
KilbourneAM, JusticeAC, RabeneckLet al.General medical and psychiatric co-morbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol, 2001; 54:S22–28.
16.
AlencastroPR, FuchsSC, WolffFHet al.Independent predictors of metabolic syndrome in HIV-infected patients. AIDS Patient Care STDs, 2011; 25:627–634.
17.
BackusLI, BoothroydD, PhilipsBet al.Assessment of the quality of diabetes care for HIV-infected patients in a national health care system. AIDS Patient Care STDs, 2011; 25:203–206.
18.
VanceD, LarsenKI, EagertonGet al.Co-morbidities and cognitive functioning: Implications for nursing research and practice. J Neurosci Nurs, 2011; 43:215–224.
19.
DeeksSG, PhillipsAN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ, 2009; 338:288–292.
20.
GuaraldiG, OrlandoG, ZonaSet al.Premature age-related co-morbidities among HIV-infected persons compared with the general population. Clin Infect Dis, 2011; 53:1120–1126.
21.
OurslerKK, GouletJL, CrystalSet al.Association of age and co-morbidity with physical function in HIV-infected and uninfected patients: Results from the Veterans Aging Cohort Study. AIDS Patient Care STDs, 2011; 25:13–20.
22.
GouletJL, FultzSL, RimlandDet al.Do patterns of co-morbidity vary by HIV status, age, and HIV severity?Clin Infect Dis, 2007; 45:1593–1601.
23.
HasseB, LedergerberB, FurrerHet al.Morbidity and aging in HIV-infected persons: The Swiss HIV cohort study. Clin Infect Dis, 2011; 53:1130–1139.
24.
WeissJJ, OsorioG, RyanEet al.Prevalence and patient awareness of medical co-morbidities in an urban AIDS clinic. AIDS Patient Care STDs, 2010; 24:39–48.
25.
PetersL, NeuhausJ, MocroftAet al.Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis co-infected persons interrupting antiretroviral therapy in the SMART study. Antivir Ther, 2011; 16:667–675.
26.
OurslerKK, GouletJL, LeafDAet al.Association of co-morbidity with physical disability in older HIV-infected adults. AIDS Patient Care STDS, 2006; 20:782–791.
27.
WoodsSP, DawsonMS, WeberEet al.The semantic relatedness of cue-intention pairings influences event-based prospective memory failures in older adults with HIV infection. J Clin Exp Neuropsychol, 2010; 32:398–407.
28.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th. Washington, D.C.: American Psychiatric Association, 1994.
29.
World Health Organization. Composite International Diagnostic Interview (CIDI, version 2.1)Geneva, Switzerland: WHO, 1998.
30.
WechslerD. Wechsler Test of Adult Reading. San Antonio, TX: Psychological Corporation, 2001.
31.
HallSF. A user's guide to selecting a co-morbidity index for clinical research. J Clin Epidemiol, 2005; 59:849–855.
32.
SkiestDJ, RubinstienE, CarleyNet al.The importance of co-morbidity in HIV-infected patients over 55: A retrospective case-control study. Am J Med, 1996; 101:605–611.
33.
LohseN, GerstoftJ, KronborgGet al.Co-morbidity acquired before HIV diagnosis and mortality in persons infected and uninfected with HIV: A Danish population-based cohort study. J Acquir Immune Defic Syndr, 2011; 57:334–339.
34.
TumbarelloM, RabagliatiR, de Gaetano DonatiKet al.Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active anti retroviral yherapy. BMC Infect Dis, 2004; 4:46.
35.
CharlsonME, PompeiP, AlesKLet al.A new method of classifying prognostic co-morbidity in longitudinal studies: Development and validation. J Chronic Dis, 1987; 40:373–383.
36.
ZavasckiAP, FuchsSC. The need for reappraisal of AIDS score weight of Charlson co-morbidity index. J Clin Epidemiol, 2007; 60:867–868.
37.
DeyoRA, CherkinDC, CiolMA. Adapting a clinical co-morbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol, 1992; 45:613–619.
38.
HeatonRK, CliffordDB, FranklinDRet al.HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology, 2010; 75:2087–2096.
39.
HeatonRK, FranklinDR, EllisEJet al.HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J Neurovirol, 2011; 17:3–16.
40.
AntinoriA, ArendtG, BeckerJTet al.Updated research nosology for HIV-associated neurocognitive disorders. Neurology, 2007; 69:1789–1799.
41.
WoodsSP, MorganEE, DawsonMet al.Action (verb) fluency predicts dependence in instrumental activities of daily living in persons infected with HIV-1. J Clin Exp Neuropsychol, 2006; 28:1030–1042.
42.
WoodsSP, RippethJD, FrolABet al.Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol, 2004; 26:759–778.
43.
LawtonMP, BrodyEM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist, 1969; 9:179–186.
44.
HeatonRK, MarcotteTD, Rivera-MindtMet al.The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc, 2004; 10:317–331.
45.
WoodsSP, IudicelloJE, MoranLMet al.HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology, 2008; 22:110–117.
46.
McNairDM, LorrM, DropplemanLF. Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service, 1981.
47.
BingEG, HaysRD, JacobsonLPet al.Health-related quality of life among people with HIV disease: Results from the Multicenter AIDS Cohort Study. Qual Life Res, 2000; 9:55–63.
48.
LampingDL. Methods for measuring outcomes to evaluate interventions to improve health-related quality of life in HIV infection. Psychol Health, 1994; 9:31–49.
49.
JiaH, UpholdCR, WuSet al.Health-related quality of life among men with HIV infection: Effects of social support, coping, and depression. AIDS Patient Care STDs, 2004; 18:594–603.
50.
NokesKM. Symptom disclosure by older HIV-infected persons. J Assoc Nurses AIDS Care, 2011; 22:186–192.
51.
GrinspoonS, CarrA. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med, 2005; 352:48–62.
52.
IsomaaB, AlmgrenP, TuomiTet al.Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001; 24:683–689.
53.
MonroeAK, ChanderG, MooreRD. Control of medical co-morbidities in individuals with HIV. J Acquir Immune Defic Syndr, 2011; 58:458–452.
54.
GrabarS, KousignianI, SobelAet al.Immunological and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS, 2004; 18:2029–2038.
55.
ReekieJ. Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and nonacquired immunodeficiency syndromes-defining malignancies. Cancer, 2010; 116:5306–5315.
56.
PalellaFJJr, BakerRK, MoormanACet al.Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr, 2006; 43:27–34.
57.
IudicelloJE, WoodsSP, DeutschR, GrantI. The HNRP Group. Combined effects of aging and HIV infection on semantic verbal fluency: A view of the cortical hypothesis through the lens of clustering and switching. J Clin Exp Neuropsychol, 2012; 34:476–488.
58.
BarclayTR, HinkinCH, CastellonSAet al.Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol, 2007; 26:40–49.
59.
ThamesAD, KimMS, BeckerBWet al.Medication and finance management among HIV-infected adults: The impact of age and cognition. J Clin Exp Neuropsychol, 2011; 33:200–209.
60.
SchusterRM, GonzalezR. Substance abuse, hepatitis C, and aging in HIV: Common cofactors that contribute to neurobehavioral disturbances. Neurobehav HIV Med, 2012; 4:15–34.
61.
GrunfeldC, DelaneyJA, WankeCet al.Preclinical atherosclerosis due to HIV infection: Carotid intima-medial thickness measurements from the FRAM study. AIDS, 2009; 23:1841–1849.
62.
KamatR, WoodsSP, MarcotteTDet al.Implications of apathy for everyday functioning outcomes in persons living with HIV infection. Arch Clin Neuropsychol, 2012; 27:520–531.
63.
TateD, PaulRH, FlaniganTPet al.The impact of apathy and depression on quality of life in patients infected with HIV. AIDS Patient Care STDS, 2003; 17:115–120.
64.
ZisookS, PeterkinJ, GogginKJet al.Treatment of major depression in HIV-seropositive men. J Clin Psychiatry, 1998; 59:217–224.
65.
NeidigJL, SmithBA, BrashersDE. Aerobic exercise training for depressive symptom management in adults living with HIV infection. J Assoc Nurses AIDS Care, 2003; 14:30–40.
66.
DoyleK, WeberE, AtkinsonJH, GrantI, WoodsSP. The HNRP Group. Aging, prospective memory, and health-related quality of life in HIV infection. AIDS Behav, 2012; 16:2309–2318.
67.
EllisRJ, DeutschR, HeatonRKet al.Neurocognitive impairment is an independent risk factor for death in HIV infection. Arch Neurol, 1997; 54:416–424.
68.
TozziV, BalestraP, SerrainoDet al.Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses, 2005; 21:706–713.
69.
CederfjällC, Languis-EklöfA, LidmanK, WredlingR. Gender difference in perceived health-related quality of life among patients with HIV infection. AIDS Patient Care STDS, 2001; 15:31–39.
70.
O'KeefeEA, WoodR. The impact of human immunodeficiency virus (HIV) on quality of life in a multiracial South African population. Qual Life Res, 1996; 5:275–280.
71.
HolzemerWL, Gygax SpicerJ, Skodol WilsonH, KemppainenJK, ColemanC. Validation of the quality of life scale: Living with HIV. J Adv Nurs, 1998; 28:622–630.
72.
Health and Human Services Agency. HIV/AIDS Epidemiology Report, 2012. San Diego: County of San Diego Health and Human Services Agency (HHSA), 2012.
73.
CampsmithML, NakashimaAK, DavidsonAJ. Self-reported health-related quality of life in persons with HIV infection: Results from a multi-site interview project. Health Qual Life Outcomes, 2003; 1:12.
74.
SørensenK, Van den BrouckeS, FullamJet al.Health literacy and public health: A systematic review and integration of definitions and models. BMC Public Health, 2012; 25:12–80.
75.
Friis-MøllerN, SabinCA, WeberRet al.Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med, 2003; 349:1993–2003.
76.
MocroftA, ReissP, GasiorowskiJet al.Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr, 2010; 55:262–270.
